Business Wire

Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador

26.1.2021 14:00:00 EET | Business Wire | Press release

Share

Aqua Lung, the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, today announced world-renowned wildlife photographer and conservationist Paul Nicklen is joining the brand as a global ocean ambassador. As part of the partnership, Nicklen will exclusively use Aqua Lung, Apeks, and O.ME.R. products during all dive expeditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005122/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Aqua Lung global ocean ambassador and SeaLegacy co-founder, Paul Nicklen with co-founder and President of SeaLegacy, Cristina Mittermeier. Photo credit: Joe Leahy

Nicklen, best-known for his incomparable underwater photography and ocean conservation efforts, will utilize the full range of industry-leading Aqua Lung, Apeks and O.ME.R. products from wetsuits, masks and fins to technical gear and regulators. Helping to grow the brand globally, Nicklen joins an elite roster of ambassadors at Aqua Lung including, Philippe Cousteau Jr., Ashlan Gorse Cousteau, and Greg Lecoeur.

“From day one, the Aqua Lung family has been kind and unwavering in their support of our mission to build community and restore the health and abundance of our oceans,” said Nicklen. “Personally, I love the simplicity and quality of the Aqua Lung products and I’m grateful the entire SeaLegacy team gets to use them. Most importantly, the products are reliable and give me the ability to focus on filming and being a photographer and conservationist.”

Paul Nicklen is a Canadian photographer and marine biologist specializing in the polar regions and their wildlife. Nicklen has completed more than 20 assignments for National Geographic and in 2014, co-founded SeaLegacy, a non-profit organization that propelled ocean conservation onto the world stage through the power of visual storytelling, impact campaigns and the funding of sustainability projects. In 2019, Nicklen was inducted into the International Photography Hall of and in that same year, was appointed to the Order of Canada.

“We are thrilled to welcome Paul Nicklen to the Aqua Lung family,” said Laurent Boury, Senior Vice President of Brands for the Aqua Lung Group. “Paul is an incredibly talented photographer and an important voice in ocean conservation, and we are honored that he chooses to use Aqua Lung, Apeks, and O.ME.R. products to further his work.”

Nicklen and the crew from SeaLegacy are slated to spend the next six months in the Bahamas, focusing on the development of an immersive content series to inspire and galvanize a global audience, shedding light on critical threats, tipping points, and scalable solutions unique to the region. Against the backdrop of Hurricane Dorian’s still ongoing recovery efforts and the ongoing Covid-19 pandemic, Nicklen and his team are documenting one of the most complex, yet promising, conservation stories as it unfolds. Using SeaLegacy’s storytelling expertise and Only One’s data-driven content delivery formula, this expedition will build a robust library of assets and supporting content that can be organized into actionable narratives and educational curriculum.

To learn more or to see Nicklen’s work, go to paulnicklen.com or follow him on Instagram. For more information about Aqua Lung products, visit AquaLung.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lauren Schuil
lschuil@aqualung.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye